

BRIEF REPORT

Open Access



Influenza vaccine effectiveness in patients hospitalized with severe acute respiratory infection in Lithuania during the 2019–2020 influenza season: a test negative case – control study

Roberta Vaikutyte^{1*}, Monika Kuliese¹, Aukse Mickiene¹, Ligita Jancoriene^{2,3}, Birute Zablockiene^{2,3}, Giedre Gefenaite^{1,4} and Study group

Abstract

Background Influenza is a contagious viral airborne disease that adds to the clinical and economic burden on the healthcare system. It could be prevented substantially by seasonal influenza vaccination. Seasonal influenza vaccine effectiveness (SIVE) varies a lot and should therefore be monitored. This report aims to update age-stratified SIVE estimates among patients hospitalized due to severe acute respiratory infection (SARI) during the 2019–2020 influenza season.

Methods We performed a test-negative case-control study between December 2019 and April 2020 influenza season. We estimated SIVE and its 95% confidence intervals (95% CI) with logistic regression as (1-odds ratio)*100%. The models were adjusted for covariates that changed the unadjusted SIVE by $\geq 10\%$.

Results Among 84 participants, 32 (38.1%) were influenza positive, mostly with A(H1N1)pdm09 (25 cases; 78.1%). SIVE against any influenza adjusted for age and heart disease was 39.2% (95% CI: -119.3%, 83.1%). Age-stratified point estimates adjusted for heart diseases indicated different SIVE, and were 64.0% (95% CI: -309.2%, 96.8%) and 21.6% (95% CI: -252.2%, 82.6%) for 18–64 and ≥ 65 year-old participants, respectively.

Conclusions The point estimates suggested low to moderate SIVE against any influenza among hospitalized 18–64-year-old SARI participants, while low estimates were found in the ≥ 65 -year-old group. Although broad SIVE confidence intervals indicate a small sample size and therefore the results can serve only as indicator, they are in line with the estimates reported by other studies during the 2019–2020 season.

Keywords Influenza, Vaccine effectiveness, Hospital surveillance, Test-negative design

*Correspondence:

Roberta Vaikutyte
roberta.vaikutyte@lsmu.lt

¹Department of Infectious Diseases, Lithuanian University of Health Sciences, Baltijos Street 120, Kaunas 47116, Lithuania

²Clinic of Infectious Diseases and Dermatovenereology, Institute of Clinical Medicine, Faculty of Medicine, Vilnius University, Santariskiu street 14, Vilnius 08406, Lithuania

³Center of Infectious Diseases, Vilnius University Hospital Santaros Klinikos, Santariskiu Street 14, Vilnius 08406, Lithuania

⁴Department of Health Sciences, Faculty of Medicine, Lund University, Box 157, Lund 22100, Sweden



© The Author(s) 2023. **Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>. The Creative Commons Public Domain Dedication waiver (<http://creativecommons.org/publicdomain/zero/1.0/>) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Introduction

Influenza is one of the most common, contagious viral airborne diseases that adds a significant burden on the healthcare system by leading to severe complications such as pneumonia, respiratory failure, requiring hospitalization and even death [1, 2]. Our previous study showed that 49% of hospitalizations due to SARI during the influenza season were positive for influenza [3]. While 48% and 69% of SARI patients were influenza positive in the two infectious diseases departments, as high as 18% and 29% of patients in geriatric and internal disease departments, respectively were positive as well. Such high influenza positivity in the latter departments dedicated to noncommunicable diseases is striking and points to that the influenza disease burden is underestimated.

Annual vaccination against influenza is recommended for everyone, and it is especially promoted among people with an increased risk of attracting influenza or suffering from its complications. Globally, influenza vaccination rates have been gradually increasing over the last decades [4], between 2004 and 2013 the total number of distributed seasonal influenza vaccine doses increased by 87% (from approximately 262 to 490 million). In Lithuania, everyone over 65 years old, people with underlying medical conditions, pregnant women and health care workers are eligible to get vaccinated free of charge as part of the national vaccination campaign. Between 2013 and 2014 and 2020–2021 influenza seasons vaccination rates among the risk groups in Lithuania more than doubled [5, 6], yet the coverage in the general population is less than 10%. Vaccine coverage by specific risk groups in Lithuania is currently not available. However, based on the reported absolute number of vaccinated individuals over 65 years old and the number of people aged over 65 in Lithuania in 2019, we estimated that the 2019–2020 influenza season vaccination rate for this age group was 18,7% [7, 8].

Seasonal influenza vaccine effectiveness (SIVE) is known to vary across seasons [9, 10]. One of the reasons is a mismatch between the vaccine strains and the circulating influenza strains [11]. It is also possible that the reliance on egg passaging for vaccine production can render additional mutations during the manufacturing process and therefore diminish SIVE [11, 12]. Next, people recommended to receive annual influenza vaccination often have a hampered immune system due to immunosenescence along the process of ageing, underlying medical or immunocompromised conditions, leading to weaker and shorter immunity following vaccination [12]. Finally, the timing between vaccination and the encounter with the virus is also important [13, 14]. The highest VE is observed shortly after vaccination (i.e., within 14 days), followed by six to eleven percent monthly decline, and remaining greater than zero for at least five to six

months post-vaccination. There is evidence that SIVE wanes during the course of a single season [14].

It is important to track changes in SIVE between the seasons to understand its determinants as well as to further guide influenza prevention policies and strategies locally and globally. For this reason, in Lithuania SIVE was monitored as part of the collaboration with the I-MOVE network (Influenza – Monitoring Vaccine Effectiveness in Europe; <https://www.imoveflu.org/>) [15–17]. SIVE studies conducted by our study site contribute to public health policy and practice (inter) nationally, currently monitoring both, influenza and COVID-19 vaccine effectiveness. The aim of the current study was to continue SIVE surveillance in Lithuania through assessment of SIVE during the 2019–2020 influenza season.

Methods

Study design

We performed a test-negative case-control study among patients hospitalized with SARI in Kaunas Hospital of the Lithuanian University of Health Sciences and Vilnius University Hospital Santaros Clinics between December, 2019 and April, 2020. Cases were influenza positive patients confirmed by reverse transcription polymerase chain reaction (RT-PCR), and controls were influenza negative. For more details about the study design see elsewhere [16, 17].

The inclusion criteria were:

- Being 18–64 years old and having at least one underlying medical condition (heart, lung, rheumatologic, kidney diseases, diabetes, cancer, stroke, immunodeficiency and solid organ recipients, anemia, dementia) or being ≥ 65 years old; and
- Being hospitalized due to SARI with at least one of the systemic symptoms (fever, myalgia, malaise, headache) or deterioration of general condition or deterioration of functional status, and at least one of the respiratory symptoms (sore throat, cough or dyspnea) for more than 24 h; and
- Being swabbed within ≤ 7 days after self-reported disease onset; and
- Not having had laboratory confirmed SARS-CoV-2 disease previously.

Statistical analysis

Demographic, clinical and lifestyle characteristics (see Table 1) were collected to control for potential confounding. The differences between the characteristics of cases and controls were tested by Chi-square, Fisher's Exact (2-sided) and Mann-Whitney tests (considered statistically significant at alpha level of $< 5\%$). SIVE was estimated by logistic regression. The analysis was adjusted for (a set of) potential confounders if upon adjustment one by one they changed SIVE estimate by $\geq 10\%$.

Table 1 Demographic and clinical characteristics of controls and influenza cases

		Influenza negative N = 52 (61.9%)	Influenza positive N = 32 (38.1%)	p-value
Sex	Female	30 (35.7)	16 (19.0)	0.49 _a
Age, median (1st ; 3rd quartile)		72.5 (62.5; 82.8)	66 (43.5; 80.5)	0.15 _c
Age ≥ 65 y. o.		36 (42.9)	17 (20.2)	0.14 _a
SIV in the current season		12 (14.3)	4 (4.8)	0.23 _a
Current smoker		11 (13.1)	5 (6.0)	0.53 _a
At least one underlying medical condition:		49 (58.3)	28 (33.3)	0.42 _b
Heart diseases		37 (44.1)	14 (16.7)	0.01 _a
Diabetes		11 (13.1)	5 (6.0)	0.53 _a
Cancer		12 (14.3)	6 (7.1)	0.64 _a
Hematologic cancer		1 (1.2)	2 (2.4)	0.56 _b
Lung diseases		12 (14.3)	4 (4.8)	0.23 _a
Renal diseases		10 (11.9)	3 (3.6)	0.35 _b
Dementia		6 (7.1)	1 (1.2)	0.24 _b
Cirrhosis		2 (2.4)	0 (0.0)	0.52 _b
Anemia		6 (7.1)	1 (1.2)	0.24 _b
Immunodeficiency and solid organ recipients		2 (2.4)	4 (4.8)	0.20 _b
Obesity (BMI ≥ 30)		16 (19.3)	8 (9.5)	0.57 _a

a - Chi-square test; b - Fisher's Exact test (2-sided); c - Mann-Whitney test

SIV - seasonal influenza vaccination

Table 2 Seasonal influenza vaccine effectiveness by age groups

	Unadjusted SIVE %	95% CI	p-value of the unadjusted model	Adjusted SIVE %	95% CI	p-value of the adjusted model
Any age	52.4	-63.0 to 86.1	0.237	39.2*	-119.3 to 83.1	0.447
Age 18–64 years	69.0	-236.4 to 97.2	0.335	64.0**	-309.2 to 96.8	0.410
Age ≥ 65 years	35.7	-176.1 to 85.0	0.552	21.6**	-252.2 to 82.6	0.751

*Adjusted for heart diseases, age

** Adjusted for heart diseases

Results

Eighty-four participants were included in the study, of which 32 (38.1%) were influenza positive. The most common influenza subtype was A(H1N1)pdm09 (25 cases; 78.1%), followed by A(H3N2) (5;15.6%) and B/Victoria (1 case).

While the results were not statistically significant, compared to controls, influenza cases were less often vaccinated, more often male and about six years younger (see Table 1). Except for hematologic cancer and immunodeficiency, underlying medical conditions were more prevalent among the controls, with only heart disease reaching statistical significance.

In 2019–2020 season unadjusted SIVE against any influenza among all participants was 52.4% (95% CI: -63.0%, 86.1%), which upon adjustment for potential confounders (i.e. heart diseases and age) decreased to 39.2% (95% CI: -119.3%, 83.1%). Adjusted SIVE estimates against any influenza were 64.0% (95% CI: -309.2%, 96.8%) and 21.6% (95% CI: -252.2%, 82.6%) for 18–64 and ≥ 65 year-old participants, respectively (Table 2).

Discussion

This study aimed to estimate SIVE in SARI patients for 2019–2020 influenza season. We found low to moderate SIVE against influenza among hospitalized patients. The age stratified analysis pointed to lower SIVE in older (21.6%) than in younger (64.0%) participants.

The point estimates from our study were in line with those reported by the I-MOVE multicenter study during the 2019–2020 season, where SIVE for all ages was found to vary between 29% and 61% against any influenza subtype, with somewhat lower estimates in older adults [18]. Studies from the United States and India also reported higher SIVE in younger than in older adults [19], which was possibly explained by the circulation of influenza B subtypes and the vaccine mismatch [20, 21].

According to the Lithuanian Compulsory Health Insurance Fund data, the incidence of clinically diagnosed influenza among adults had decreased from 21.5 cases per 1000 population in 2018, to 4.9 cases per 1000 population in 2020 [22, 23]. Similar decrease of influenza and other respiratory viral infections was reported in several other countries [24–26]. As compared to previous

seasons, there were less SARI cases (SARS-CoV-2 cases excluded) requiring hospitalization during the 2019–2020 season both in Lithuania and worldwide [27]. While implementation of protective measures, such as wearing masks, washing and disinfecting hands more frequently, limiting travel and declaration of quarantine were likely contributors of such decrease [24], it might primarily be explained by the emergence and spread of SARS-CoV-2 at the beginning of 2020. Another reason for such decrease could be reduced influenza testing: as compared to previous season, the number of specimens tested with PCR in Lithuania during the 2019–2020 season reduced by 35% [28, 29]. During the 2020–2021 season, the number of laboratory-confirmed influenza cases in Lithuania dropped even further, with only 302 cases reported nationally [6]. Some cases of influenza could have also been masked by SARS-CoV-2 infection: studies reported influenza and SARS-CoV-2 coinfection to vary between 0.8 and 1.96%, and as high as 22.3% in severe patients [26, 30–32].

Several strengths and limitations of the current study should be mentioned. Due to a rather small sample size, and therefore broad confidence intervals, SIVE results of the current study should be interpreted with some caution. Stratification into different risks groups resulted in even smaller samples, limiting statistical power to explore further mechanisms leading to specific SIVE. As since the emergence of SARS-CoV-2 influenza testing was not performed, we were not able to include SARS-CoV-2 cases and so potential co-infections into the study and to estimate SARS-CoV-2 impact on SIVE.

One of the main strengths of the current study was using the generic protocol when it comes to the study design, data collection and analysis procedures [33], which makes the results easily comparable across the seasons and other studies that have adopted the protocol. Next, influenza confirmation was done by RT-PCR and the participants were recruited within seven days after SARI symptoms' onset, which was expected to reduce the probability of false-negative results. Furthermore, cases were recruited before taking the swab and learning the results this way minimizing the classification bias.

Conclusion

During the 2019–2020 season, which overlapped with the emergence of SARS-CoV-2 virus, there was a decline of influenza cases in Lithuania. The main circulating influenza subtype during the 2019–2020 season in Lithuania was A(H1N1)pdm09. The point estimates suggested low and moderate SIVE against any influenza among the older and younger hospitalized participants, respectively. Close monitoring of both influenza, SARS-CoV-2 and other respiratory pathogens incidence and co-infection

data is an essential next step in better understanding SIVE estimates.

Abbreviations

CI	confidence intervals
RT-PCR	Reverse transcription polymerase chain reaction
SARI	Severe acute respiratory infection
SIVE	Seasonal influenza vaccine effectiveness

Acknowledgements

Study group: Department of Geriatrics, Lithuanian University of Health Sciences, Kaunas, Lithuania: Vita Lesauskaite, Gyte Damuleviciene; Department of Infectious Diseases, Lithuanian University of Health Sciences, Kaunas, Lithuania: Kotryna Krupeckaite, Ieva Braduniene; Department of Internal Diseases, Kaunas Hospital, Kaunas, Lithuania: Alfredas Bagdonas. Participating Investigators collected data and provided and cared for study patients.

Authors' contributions

Conceptualization, M.K., A.M., G.G., L.J., and B.Z.; methodology, M.K., A.M., G.G., L.J., and B.Z.; formal analysis, R.V., M.K. and G.G.; resources, M.K.; writing - original draft preparation, R.V., M.K. and G.G.; writing - review and editing, M.K., G.G., A.M., L.J. and B.Z.; project administration and funding acquisition: M.K., A.M., and G.G.; data acquisition: M.K., L.J., B.Z., and all authors of the study group. All mentioned authors have read and approved the final version.

Funding

The study was supported by The European Commission Horizon 2020 program (agreement 634446) and Epicconcept.

Data availability

The data presented in this study are available in insert article.

Declarations

Ethics approval and consent to participate

This study was conducted in line with the Lithuanian legislation on research with humans and the Declaration of Helsinki. Kaunas Regional Biomedical Research Ethics Committee approval was obtained (05/11/2019, (P7-158200-04-476-138/2012)). Informed consent was obtained from all participating subjects involved in the study.

Competing interests

Authors declare no conflict of interest. Ligita Jancoriene and Aukse Mickiene received consulting fees and honorarium for lectures outside the submitted work.

Received: 31 December 2022 / Accepted: 20 March 2023

Published online: 12 April 2023

References

1. Rolfes MA, Foppa IM, Garg S, Flannery B, Brammer L, Singleton JA et al. Annual estimates of the burden of seasonal influenza in the United States: A tool for strengthening influenza surveillance and preparedness.
2. Patel MS, Volpp KG, Small DS, Wynne C, Zhu J, Yang L, et al. Using active choice within the Electronic Health Record to increase Influenza Vaccination Rates. *J Gen Intern Med.* 2017;32(7):790–5.
3. Kuliešė M. Seasonal Influenza and Influenza Vaccine Effectiveness among Risk Group Patients Hospitalized Due to Acute Severe Respiratory Infection in Lithuania 2015–2020. 2021.
4. Palache A, Oriol-Mathieu V, Fino M, Xydia-Charmanta M. Seasonal influenza vaccine dose distribution in 195 countries (2004–2013): little progress in estimated global vaccination coverage. *Vaccine.* 2015 Oct;13(42):5598–605.
5. Lithuanian National Public Health Center under the Ministry of Health. Sezonine gripo vakcina paskiepytų asmenų skaičius Leituvoje (Number of vaccinated people with seasonal influenza vaccine).

6. Lithuanian National Public Health Center under the Ministry of Health Report on Influenza Vaccination [Internet]. Available from: <https://nvsc.lrv.lt/lt/naujienos/lietuvoje-sparciai-auga-sergamumas-persalimo-ligomis>
7. National Public Health Center under the Ministry of Health. Epidemiologinė 2021–2022 metų gripo sezono analizė (Epidemiological 2021–2022 Influenza season analysis). 2022.
8. Statistics Lithuania State Data Agency. Official Statistics Portal.
9. Lewnard JA, Cobey S. Immune History and Influenza Vaccine Effectiveness [Internet]. *Vaccines* 2018, 6(2), 28; [cited 2022 Jan 11]. Available from: <https://www.mdpi.com/2076-393X/6/2/28>
10. Monto AS, Petrie JG. Improving Influenza Vaccine Effectiveness: Ways to Begin Solving the Problem. *Clinical Infectious Diseases*. 2019 Nov;69(10):1824–6.
11. Erbeling EJ, Post DJ, Stemmy EJ, Roberts PC, Augustine AD, Ferguson S et al. A Universal Influenza Vaccine: The Strategic Plan for the National Institute of Allergy and Infectious Diseases. *J Infect Dis*. 2018 Jul 2;218(3):347.
12. Boikos C, Imran M, Nguyen VH, Ducruet T, Sylvester GC, Mansi JA. Effectiveness of the Cell-Derived Inactivated Quadrivalent Influenza Vaccine in Individuals at High Risk of Influenza Complications in the 2018–2019 United States Influenza Season. *Open Forum Infect Dis*. 2021 Jul 1;8(7).
13. Ferdinands JM, Fry AM, Reynolds S, Petrie JG, Flannery B, Jackson ML et al. Intra-season Waning of Influenza Vaccine Protection: Evidence From the US Influenza Vaccine Effectiveness Network, 2011–2012 Through 2014–2015. *Clinical Infectious Diseases*. 2017 Mar 1;64(5):544–50.
14. Thomas Ray G, Lewis N, Klein NP, Daley MF, Wang SV, Kulldorff M, et al. Intra-season waning of Influenza Vaccine Effectiveness. *Clin Infect Dis*. 2019 May;68(2):1623–30.
15. Gefenaite G, Rahamat-Langendoen J, Ambrozaitis A, Mickiene A, Jancoriene L, Kuliese M et al. Seasonal influenza vaccine effectiveness against influenza in 2012–2013: A hospital-based case-control study in Lithuania. *Vaccine*. 2014 Feb;32(7):857–63.
16. Kuliese M, Jancoriene L, Grimalauskaite R, Zablockiene B, Damuleviciene G, Velyvyte D et al. Seasonal influenza vaccine effectiveness against laboratory-confirmed influenza in 2015–2016: A hospital-based test-negative case-control study in Lithuania. *BMJ Open*. 2017 Oct 1;7(10).
17. Kuliese M, Mickiene A, Jancoriene L, Zablockiene B, Gefenaite G. Age-specific seasonal influenza vaccine effectiveness against different influenza subtypes in the hospitalized population in Lithuania during the 2015–2019 influenza seasons. *Vaccines (Basel)*. 2021 May 1;9(5).
18. Rose A, Kissling E, Emborg HD, Larrauri A, McMenamin J, Pozo F et al. Interim 2019/20 influenza vaccine effectiveness: six European studies, September 2019 to January 2020. *Eurosurveillance*. 2020 Mar 12;25(10).
19. Grijalva CG, Feldstein LR, Talbot HK, Aboodi M, Baughman AH, Brown SM, et al. Influenza vaccine effectiveness for Prevention of severe Influenza-Associated illness among adults in the United States, 2019–2020: a test-negative study. *Clin Infect Dis*. 2021 Oct;20(8):1459–68.
20. Tenforde MW, Kondor RJG, Chung JR, Zimmerman RK, Nowalk MP, Jackson ML et al. Effect of Antigenic Drift on Influenza Vaccine Effectiveness in the United States-2019-2020. *Clin Infect Dis*. 2021 Dec;73(11):e4244–50.
21. Mir H, Haq I, Koul PA. Poor Vaccine Effectiveness against Influenza B-Related Severe Acute Respiratory Infection in a Temperate North Indian State (2019–2020): A Call for Further Data for Possible Vaccines with Closer Match. *Vaccines (Basel)*. 2021 Oct 1;9(10).
22. Lithuanian Ministry of Health Health Information Centre of Institute of Hygiene. Health Statistics of Lithuania 2020. 2020
23. The Centre for Communicable Diseases and AIDS. Sergamumas gripu ir ūminėmis viršutinių kvėpavimo takų infekcijomis (Mor-bidity with Influenza and Acute Respiratory Infections) [Inter-net]. [cited 2022 Aug 6]. Available from: <http://www.ulac.lt/sergamumas-gripu-ir-uminemis-virsutiniu-kepvavimo>
24. Olsen SJ, Winn AK, Budd AP, Prill MM, Steel J, Midgley CM et al. Changes in Influenza and Other Respiratory Virus Activity During the COVID-19 Pan-demic — United States, 2020–2021. *Morbidity and Mortality Weekly Report*. 2021 Jul 23;70(29):1013.
25. Melidou A, Pereyaslov D, Hungnes O, Proscenk K, Alm E, Adlhoeh C et al. Virological surveillance of influenza viruses in the WHO European Region in 2019/20 - Impact of the COVID-19 pandemic. *Eurosurveillance*. 2020 Nov 1;25(46).
26. Venkatram S, Alapati A, Dileep A, Diaz-Fuentes G. Change in patterns of hospitalization for influenza during COVID-19 surges. 2021
27. Olsen SJ, Azziz-Baumgartner E, Budd AP, Brammer L, Sullivan S, Pineda RF et al. Decreased influenza activity during the COVID-19 pandemic—United States, Australia, Chile, and South Africa, 2020. *American Journal of Transplan-tation*. 2020 Dec 1;20(12):3681–5.
28. National Public Health Laboratory. 2019–2020 Data on Influenza and RSV [Internet]. [cited 2022 Aug 6]. Available from: <https://nvspl.lt/veiklos-sritys/infekciniu-ligu-laboratorine-stebesena/virusai>
29. National Public Health Center under the Ministry of Health. Epidemiologinė 2021–2022 metų gripo sezono analizė. 2022
30. Hashemi SA, Safamanesh S, Ghasemzadeh-moghaddam H, Ghafouri M, Azimian A. High prevalence of SARS-CoV-2 and influenza A virus (H1N1) coinfection in dead patients in Northeastern Iran. *J Med Virol*. 2021 Feb 1;93(2):1008–12.
31. Dadashi M, Khaleghnejad S, Abedi Elkhichi P, Goudarzi M, Goudarzi H, Taghavi A et al. COVID-19 and Influenza Co-infection: A Systematic Review and Meta-Analysis. *Front Med (Lausanne)*. 2021 Jun 25;8.
32. Castillo EM, Coyne CJ, Brennan JJ, Christian MA, Tomaszewski A. Rates of coinfection with other respiratory pathogens in patients positive for coronavirus disease 2019 (COVID-19). 2020
33. I-MOVE. Protocol for hospital-based, test-negative case-control studies to measure seasonal influenza vaccine effectiveness against influenza labora-tory-confirmed SARI hospitalisation among the elderly across the European Union and European Economic Area Member S. 2019.

Publisher's note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.